An Open-Label, Multicenter, Phase I/II Study of Pazopanib in Combination With Paclitaxel in First-Line Treatment of Subjects With Stage IIIBwet/IV Non-Small Cell Lung Cancer.

Trial Profile

An Open-Label, Multicenter, Phase I/II Study of Pazopanib in Combination With Paclitaxel in First-Line Treatment of Subjects With Stage IIIBwet/IV Non-Small Cell Lung Cancer.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 01 Feb 2015

At a glance

  • Drugs Paclitaxel (Primary) ; Pazopanib (Primary)
  • Indications Malignant melanoma; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 01 Oct 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Aug 2012 Planned end date changed from 1 Jul 2012 to 1 Oct 2012 as reported by ClinicalTrials.gov.
    • 18 May 2012 Phase II part of the study will not be progressed as documented in Protocol Amendment 01.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top